| Ytd | 63.34% | |
| 1y | 150.79% |
| Open | 41.05 | Prev Close | 41.03 | Low | 41.03 | High | 41.05 | Mkt Cap | 5.25B |
| Vol | 28.64M | Avg Vol | 7.54M | EPS | 1.02 | P/E | 38.71 | Forward P/E | 46.30 |
| Beta | -0.25 | Short Ratio | 1.15 | Inst. Own | 110.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 33.60 | 200-d Avg | 26.15 | 1yr Est | 40.92 |
APLS News
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceutica
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAP
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260507-1483310/1483310_tph-apl
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating th
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & A
Stocks AVNS, APLS, and CERS in healthcare sector flashing warning to momentum-sensitive investors. H
The Nasdaq Composite surged 15.3% in April, marking its strongest monthly gain since the early pande
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde a
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) have received an average re
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for
Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boostin
Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuti
Pre-Market Stock Futures: Risk-on appeared back, at least for the last two days, as the stock market
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) hit a new 52-week high duri
NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & As
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenu
Wall Street analysts changed outlook for top names. See all rating changes on analyst ratings page.
Top Wall Street analysts changed their outlook on top names. For a complete view of all rating chang
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. T
US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
Wall Street traded timidly on Tuesday despite another benign inflation report that reinforced expect
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.
Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announc
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly los
It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after t
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company p